Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2024-02-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
关于获得创新药HSK39775片《药物临床试验批准通知书》的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a pharmaceutical company about receiving approval for clinical trials of a new drug from the National Medical Products Administration. It contains no financial data, no detailed financial performance, no management discussion, no voting results, no regulatory certifications, and no report attachments. The document is short (938 characters) and serves as a regulatory announcement about a clinical trial approval, which is a regulatory filing type of announcement. It does not fit into categories like Annual Report, Earnings Release, or Investor Presentation. Therefore, the best classification is Regulatory Filings (RNS).
2024-02-27 Chinese
关于注销子公司澳洲海思科的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the cancellation (注销) of a subsidiary company, Haisco Pharmaceutical (Australia) Pty Ltd. It includes details about the subsidiary, the board meeting resolution approving the cancellation, and the impact on the parent company. There is no indication of financial statements or comprehensive financial reporting, nor is it a report publication or certification. The content is about a corporate action related to the company's structure and management decisions, specifically a board-approved decision. This fits best under 'Board/Management Information' (MANG), which covers announcements of changes in the company's board or senior management or significant corporate structural changes approved by the board.
2024-02-27 Chinese
关于董事辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a company director, Mr. Zheng Wei, from the board of directors of Haishike Pharmaceutical Group Co., Ltd. It includes details about the resignation, compliance with relevant laws, and the director's shareholding status. There is no financial data, report, or presentation content. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2024-02-23 Chinese
关于获得创新药HSK31858片新适应症IND申请《受理通知书》的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a pharmaceutical company about receiving an acceptance notice from the National Medical Products Administration for a new clinical trial application of an innovative drug. It includes details about the drug, its intended use, and regulatory acceptance. The document is short (1081 characters) and serves as an official announcement of a regulatory event rather than a detailed report or financial statement. It does not contain financial data, management discussion, or detailed report content. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2024-01-31 Chinese
关于获得创新药HSK16149胶囊新适应症IND申请《受理通知书》的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acceptance of an IND (Investigational New Drug) application for a new indication of an innovative drug HSK16149. It includes details about the drug, its mechanism, the disease it targets, and regulatory acceptance by the National Medical Products Administration. The document is short (1380 characters) and serves as a formal notification of regulatory acceptance rather than a detailed financial or operational report. It does not contain financial statements, management discussion, or detailed investor presentation content. It is not an annual or interim report, earnings release, or any form of shareholder meeting material. It is a regulatory announcement about a clinical trial application acceptance, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-01-30 Chinese
关于使用闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the use of idle raised funds for cash management. It details the approval by the board and supervisory committee, the amount of funds involved, investment purposes, risk control measures, and related opinions from independent directors and the sponsoring institution. The document does not contain financial statements or detailed financial performance data but rather discloses a corporate action related to the management of raised capital. It is not a full financial report, earnings release, or audit report. The document fits the category of a Capital/Financing Update (CAP) because it concerns the use and management of raised funds (募集资金) and related corporate financing activities.
2024-01-30 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.